バイオ医薬品市場の2030年までの予測：製品タイプ別、用途別、地域別の世界分析

Stratistics MRCによると、世界のバイオ医薬品市場は2023年に10億4,745万米ドルを占め、予測期間中にCAGR14.4%で成長し、2030年には26億8,605万米ドルに達すると予測されています。

バイオ医薬品は、生物学的製剤または生物製剤とも呼ばれ、細胞、生物、タンパク質などの生物から作られる医薬品です。これらの医薬品はバイオテクノロジー技術を用いて製造され、現代のヘルスケアに不可欠なものです。さらに、バイオ医薬品は個別化医療戦略の開発を可能にしました。これらの医薬品は、患者の病気の特定の分子的側面を標的とする可能性があり、患者の特定の遺伝的プロファイルや病気のサブタイプに基づいた個別化治療計画の開発を可能にします。

国際がん研究機関によると、2020年には約1,930万人が新たにがんと診断され、約1,000万人が死亡しました。がん患者は2020年から2040年にかけて47％増加すると推定されています。

拡大する科学の進歩

バイオ医薬品の研究開発は、構造生物学、遺伝子編集、ハイスループットスクリーニング法など、現在進行中の科学の進歩によって変貌を遂げています。医薬品設計は、低温電子顕微鏡や最先端のイメージング技術によってもたらされる二分子構造の理解によって助けられています。膨大なデータセットは、人工知能や機械学習を用いて分析され、創薬に関する予測を行います。さらに、CRISPR-Cas9のような合成生物学の進歩により、遺伝子治療や遺伝子編集細胞治療が可能になり、バイオ医薬品の幅が広がっています。

過剰な開発費

バイオ医薬品の開発には、調査、前臨床試験、難易度の高い臨床試験への財政投資が重要です。このような基本的なコストに加え、バイオ医薬品企業は、最先端の実験器具や特殊な製造施設といった専門的なインフラにも資金を費やさなければならず、これらすべてが開発コストを押し上げる要因となっています。さらに、バイオ医薬品開発には長期的かつ資源集約的な性質があり、1つの新薬候補に数十億米ドルを超える費用がかかることも多いため、財務上の困難はさらに深刻化しています。

臨床試験の増加と個別化医療

ゲノム科学と分子診断学の発展により、患者の遺伝子プロファイルや特定の疾患特性に合わせた治療を行う精密医療が可能になりつつあります。この戦略により、治療効果が向上し、副作用が最小限に抑えられ、患者の転帰が最適化されます。さらに腫瘍学は、バイオマーカー主導の治療が生存率と奏効率を高めていることから、個別化医療が特に有望視されている分野です。

知的財産（IP）への課題

バイオ医薬品市場は世界に展開されているため、特許、企業秘密、特許の藪が複雑に絡み合い、知的財産に関する新たな課題となっています。さらに、バイオシミラーの出現は、特許紛争や、単一の製品をカバーするために複数の特許を使用し、市場独占権の延長を提供する特許藪戦略など、新たな法的複雑性をもたらします。

COVID-19の影響：

COVID-19の大流行は、バイオ医薬品業界に様々な形で大きな影響を与えました。臨床試験の遅延、世界のサプライチェーンの混乱、パンデミック関連活動へのリソースの再集中に加えて、ワクチンと治療薬の緊急の必要性が研究開発の努力を加速させました。さらに、パンデミックはワクチン開発、抗ウイルス療法、バイオ医薬品の技術革新の重要性を浮き彫りにし、これらの分野への投資の増加につながっています。また、サプライチェーンの弱点も露呈し、企業は流通・製造計画の再考を余儀なくされました。

予測期間中、ワクチン分野が最大となる見込み

ワクチン分野は通常、市場で最大のシェアを占めています。幅広い感染症がワクチンによって予防されており、公衆衛生に不可欠です。ワクチンは、COVID-19のような現在の脅威と、インフルエンザや肝炎のような新興の脅威の両方で、よりよく知られるようになっています。特にCOVID-19のパンデミックの結果、ワクチンの世界的需要は劇的に増加しました。しかし、ワクチン市場は、mRNAワクチンのような新しいワクチンプラットフォームの創出を含む継続的な研究開発活動により、バイオ医薬品産業の拡大や公衆衛生の向上への取り組みにとって依然として不可欠です。

予測期間中、CAGRが最も高くなると予想されるがん領域

バイオ医薬品市場のCAGRが最も高いと予想されるのは、がん領域です。その主な理由は、世界のがん罹患率の上昇、標的療法や免疫療法の発展、精密医療手法の継続的な研究などです。さらに、さまざまながん種に対する新規バイオ医薬品の創出、併用療法やバイオマーカー主導型治療の可能性により、がん領域市場は大きな成長を遂げています。

最もシェアの高い地域：

世界のバイオ医薬品市場は通常、北米地域、特に米国で最大のシェアを占めています。強力な製薬産業、多額の研究開発費、発達したヘルスケアシステム、多くの患者基盤、バイオ医薬品の開発・商業化を支援する規制環境などが、この優位性の要因として挙げられています。さらに、北米には多数のバイオ医薬品企業、学術研究センター、バイオテクノロジー拠点があることも、市場シェアの大きさに影響しています。

CAGRが最も高い地域：

バイオ医薬品市場のCAGRが最も高いのはアジア太平洋地域です。中間所得層の増加、ヘルスケアコストの上昇、医薬品製造能力の向上、最先端治療に対する需要の高まりは、この業界が急成長している理由のほんの一部に過ぎないです。研究開発、臨床試験、生物学的製剤やワクチンの製造への投資により、特に中国やインドのような国々がバイオ医薬品業界の主要企業として台頭してきています。さらに、この地域の急成長は、政府の支援政策や大手製薬企業との提携も後押ししています。

無料のカスタマイズサービス

本レポートをご購読のお客様には、以下の無料カスタマイズオプションのいずれかをご利用いただけます：

• 企業プロファイル
  • 追加市場企業の包括的プロファイリング（3社まで）
  • 主要企業のSWOT分析（3社まで）
• 地域セグメンテーション
  • 顧客の関心に応じた主要国の市場推計・予測・CAGR（注：フィージビリティチェックによる）
• 競合ベンチマーキング
  • 製品ポートフォリオ、地理的プレゼンス、戦略的提携に基づく主要企業のベンチマーキング

目次

第1章 エグゼクティブサマリー

第2章 序文

• 概要
• ステークホルダー
• 調査範囲
• 調査手法
  • データマイニング
  • データ分析
  • データ検証
  • 調査アプローチ
• 調査ソース
  • 1次調査ソース
  • 2次調査ソース
  • 前提条件

第3章 市場動向分析

• 促進要因
• 抑制要因
• 機会
• 脅威
• 製品分析
• 用途分析
• 新興市場
• 新型コロナウイルス感染症（COVID-19）の影響

第4章 ポーターのファイブフォース分析

• 供給企業の交渉力
• 買い手の交渉力
• 代替品の脅威
• 新規参入業者の脅威
• 競争企業間の敵対関係

第5章 世界のバイオ医薬品市場：製品タイプ別

• モノクローナル抗体
  • 抗がんモノクローナル抗体
  • 抗炎症性モノクローナル抗体
• インターフェロン
• インスリン
• 成長因子と凝固因子
• ワクチン
  • 組換えワクチン
    • がんワクチン
    • マラリアワクチン
    • エボラワクチン
    • B型肝炎ワクチン
    • 破傷風ワクチン
    • ジフテリアワクチン
    • コレラワクチン
  • 従来のワクチン
    • ポリオワクチン
    • ポックスワクチン
• 組換え成長因子
  • エリスロポエチン
  • 顆粒球コロニー刺激因子
• 精製タンパク質
  • 白血病抑制因子（LIF）
  • P53タンパク質
  • P38タンパク質
• 組換えタンパク質
  • 血清アルブミン
  • アミロイドタンパク質
  • ディフェンシン
  • トランスフェリン
• 合成免疫調節剤
• 組換えホルモン
  • 組換えヒト成長ホルモン
  • 組換えインスリン
• 組換え酵素
  • エンテロキナーゼ
  • シクラーゼ
  • カスパーゼ
  • カテプシン
• 細胞および遺伝子治療
  • 同種異系製品
  • 自己製品
  • 無細胞製品
• 合成免疫調節剤
  • サイトカイン
  • インターフェロン
  • インターロイキン
• その他の製品タイプ

第6章 世界のバイオ医薬品市場：用途別

• 腫瘍学
• 血液疾患
• 代謝性疾患
• 感染症
• 循環器疾患
• 神経疾患
• 免疫学
• 自己免疫疾患
• ホルモン障害
• その他の用途

第7章 世界のバイオ医薬品市場：地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン
  • その他欧州
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • ニュージーランド
  • 韓国
  • その他アジア太平洋地域
• 南米
  • アルゼンチン
  • ブラジル
  • チリ
  • その他南米
• 中東とアフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • カタール
  • 南アフリカ
  • その他中東とアフリカ

第8章 主な発展

• 契約、パートナーシップ、コラボレーション、合弁事業
• 買収と合併
• 新製品の発売
• 事業拡大
• その他の主要戦略

第9章 企業プロファイル

• Merck & Co., Inc.
• Novartis AG
• Abbott Laboratories.
• Novo Nordisk A/S
• Eli Lilly and Company
• AstraZeneca PLC
• Bristol-Myers Squibb Company
• Biogen Inc.
• AbbVie Inc.
• Pfizer Inc.
• Bausch Health Companies Inc.
• F. Hoffmann-La Roche AG
• Sanofi
• Bayer AG
• Allergan plc
• Johnson & Johnson
• Amgen Inc.

List of Tables

• Table 1 Global Biopharmaceuticals Market Outlook, By Region (2021-2030) ($MN)
• Table 2 Global Biopharmaceuticals Market Outlook, By Product Type (2021-2030) ($MN)
• Table 3 Global Biopharmaceuticals Market Outlook, By Monoclonal Antibodies (2021-2030) ($MN)
• Table 4 Global Biopharmaceuticals Market Outlook, By Anti-cancer Monoclonal Antibodies (2021-2030) ($MN)
• Table 5 Global Biopharmaceuticals Market Outlook, By Anti-inflammatory Monoclonal Antibodies (2021-2030) ($MN)
• Table 6 Global Biopharmaceuticals Market Outlook, By Interferon (2021-2030) ($MN)
• Table 7 Global Biopharmaceuticals Market Outlook, By Insulin (2021-2030) ($MN)
• Table 8 Global Biopharmaceuticals Market Outlook, By Growth and Coagulation Factor (2021-2030) ($MN)
• Table 9 Global Biopharmaceuticals Market Outlook, By Vaccines (2021-2030) ($MN)
• Table 10 Global Biopharmaceuticals Market Outlook, By Recombinant Vaccines (2021-2030) ($MN)
• Table 11 Global Biopharmaceuticals Market Outlook, By Conventional Vaccines (2021-2030) ($MN)
• Table 12 Global Biopharmaceuticals Market Outlook, By Recombinant Growth Factors (2021-2030) ($MN)
• Table 13 Global Biopharmaceuticals Market Outlook, By Erythropoietin (2021-2030) ($MN)
• Table 14 Global Biopharmaceuticals Market Outlook, By Granulocyte Colony Stimulating Factor (2021-2030) ($MN)
• Table 15 Global Biopharmaceuticals Market Outlook, By Purified Proteins (2021-2030) ($MN)
• Table 16 Global Biopharmaceuticals Market Outlook, By Leukemia Inhibitory Factor (LIF) (2021-2030) ($MN)
• Table 17 Global Biopharmaceuticals Market Outlook, By P53 Protein (2021-2030) ($MN)
• Table 18 Global Biopharmaceuticals Market Outlook, By P38 Protein (2021-2030) ($MN)
• Table 19 Global Biopharmaceuticals Market Outlook, By Recombinant Proteins (2021-2030) ($MN)
• Table 20 Global Biopharmaceuticals Market Outlook, By Serum Albumin (2021-2030) ($MN)
• Table 21 Global Biopharmaceuticals Market Outlook, By Amyloid Protein (2021-2030) ($MN)
• Table 22 Global Biopharmaceuticals Market Outlook, By Defensin (2021-2030) ($MN)
• Table 23 Global Biopharmaceuticals Market Outlook, By Transferrin (2021-2030) ($MN)
• Table 24 Global Biopharmaceuticals Market Outlook, By Synthetic Immunomodulators (2021-2030) ($MN)
• Table 25 Global Biopharmaceuticals Market Outlook, By Recombinant Hormones (2021-2030) ($MN)
• Table 26 Global Biopharmaceuticals Market Outlook, By Recombinant Human Growth Hormones (2021-2030) ($MN)
• Table 27 Global Biopharmaceuticals Market Outlook, By Recombinant Insulin (2021-2030) ($MN)
• Table 28 Global Biopharmaceuticals Market Outlook, By Recombinant Enzymes (2021-2030) ($MN)
• Table 29 Global Biopharmaceuticals Market Outlook, By Enterokinase (2021-2030) ($MN)
• Table 30 Global Biopharmaceuticals Market Outlook, By Cyclase (2021-2030) ($MN)
• Table 31 Global Biopharmaceuticals Market Outlook, By Caspase (2021-2030) ($MN)
• Table 32 Global Biopharmaceuticals Market Outlook, By Cathepsin (2021-2030) ($MN)
• Table 33 Global Biopharmaceuticals Market Outlook, By Cell and Gene Therapies (2021-2030) ($MN)
• Table 34 Global Biopharmaceuticals Market Outlook, By Allogenic Products (2021-2030) ($MN)
• Table 35 Global Biopharmaceuticals Market Outlook, By Autologous Products (2021-2030) ($MN)
• Table 36 Global Biopharmaceuticals Market Outlook, By Acellular Products (2021-2030) ($MN)
• Table 37 Global Biopharmaceuticals Market Outlook, By Synthetic Immunomodulators (2021-2030) ($MN)
• Table 38 Global Biopharmaceuticals Market Outlook, By Cytokines (2021-2030) ($MN)
• Table 39 Global Biopharmaceuticals Market Outlook, By Interferons (2021-2030) ($MN)
• Table 40 Global Biopharmaceuticals Market Outlook, By Interleukins (2021-2030) ($MN)
• Table 41 Global Biopharmaceuticals Market Outlook, By Other Product Types (2021-2030) ($MN)
• Table 42 Global Biopharmaceuticals Market Outlook, By Application (2021-2030) ($MN)
• Table 43 Global Biopharmaceuticals Market Outlook, By Oncology (2021-2030) ($MN)
• Table 44 Global Biopharmaceuticals Market Outlook, By Blood disorder (2021-2030) ($MN)
• Table 45 Global Biopharmaceuticals Market Outlook, By Metabolic disease (2021-2030) ($MN)
• Table 46 Global Biopharmaceuticals Market Outlook, By Infectious disease (2021-2030) ($MN)
• Table 47 Global Biopharmaceuticals Market Outlook, By Cardiovascular disease (2021-2030) ($MN)
• Table 48 Global Biopharmaceuticals Market Outlook, By Neurological disease (2021-2030) ($MN)
• Table 49 Global Biopharmaceuticals Market Outlook, By Immunology (2021-2030) ($MN)
• Table 50 Global Biopharmaceuticals Market Outlook, By Autoimmune Disorders (2021-2030) ($MN)
• Table 51 Global Biopharmaceuticals Market Outlook, By Hormonal Disorders (2021-2030) ($MN)
• Table 52 Global Biopharmaceuticals Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.

According to Stratistics MRC, the Global Biopharmaceuticals Market is accounted for $1047.45 million in 2023 and is expected to reach $2686.05 million by 2030 growing at a CAGR of 14.4% during the forecast period. Biopharmaceuticals, also referred to as biologic drugs or biologics, are pharmaceuticals made from living things like cells, organisms, or proteins. These medications are produced using biotechnology techniques and are essential to contemporary healthcare. Moreover, biopharmaceuticals have made it possible to develop personalized medicine strategies. These medications have the potential to target particular molecular aspects of a patient's illness, enabling the development of personalized treatment plans based on the patient's particular genetic profile or disease subtype.

According to the International Agency for Research on Cancer, in the year 2020, around 19.3 million new cases of cancer were diagnosed and around 10 million cancer deaths were recorded. The cancer cases are estimated to grow by 47% from 2020 to 2040.

Market Dynamics:

Driver:

Expanding scientific advances

Biopharmaceutical R&D is being transformed by ongoing scientific advances in structural biology, gene editing, and high-throughput screening methods. Drug design is aided by the understanding of bimolecular structures provided by cryo-electron microscopy and cutting-edge imaging technologies. Massive datasets are analyzed using artificial intelligence and machine learning to make predictions about drug discovery. Additionally, gene therapies and gene-edited cell therapies have been made possible by advances in synthetic biology, such as CRISPR-Cas9, expanding the range of biopharmaceuticals.

Restraint:

Excess development costs

Financial investments in research, preclinical studies, and challenging clinical trials are significant in the development of biopharmaceuticals. In addition to these basic costs, biopharmaceutical businesses also have to spend money on specialized infrastructure, such as state-of-the-art lab tools and specialized manufacturing facilities, all of which drive up development costs. Furthermore, the lengthy and resource-intensive nature of biopharmaceutical development, where costs frequently exceed billions of dollars for a single drug candidate, further exacerbates financial difficulties.

Opportunity:

Increasing clinical trials and personalized medicine

Precision medicine, which tailors treatments to a person's genetic profile and particular disease characteristics, is being made possible by developments in genomics and molecular diagnostics. With this strategy, treatment effectiveness is improved, side effects are minimized, and patient outcomes are optimized. Moreover, oncology is a field where personalized medicine holds particular promise because biomarker-driven therapies are increasing survival and response rates.

Threat:

Challenges to intellectual property (IP)

A complex web of patents, trade secrets, and patent thickets must be negotiated by businesses due to the global nature of the biopharmaceutical market, which presents additional IP challenges. Additionally, the emergence of biosimilars brings with it new legal complexities, such as patent disputes and patent thicket strategies, where multiple patents are used to cover a single product and provide for extended market exclusivity.

COVID-19 Impact:

The COVID-19 pandemic affected the biopharmaceutical industry significantly and in a variety of ways. In addition to delaying clinical trials, disrupting global supply chains, and refocusing resources on pandemic-related activities, the urgent need for vaccines and treatments accelerated research and development efforts. Moreover, the pandemic highlighted the significance of vaccine development, antiviral therapies, and biopharmaceutical innovation, leading to increased investments in these fields. It also exposed weaknesses in supply chains, forcing businesses to reconsider their distribution and manufacturing plans.

The Vaccines segment is expected to be the largest during the forecast period

The vaccines segment typically holds the largest share of the market. A wide range of infectious diseases are prevented by vaccines, which are essential to public health. They have become more well-known for both current threats like COVID-19 and emerging ones like influenza and hepatitis. The global demand for vaccines has increased dramatically as a result of the COVID-19 pandemic in particular. However, the vaccine market is still essential to the expansion of the biopharmaceutical industry and efforts to improve public health due to ongoing research and development activities, including the creation of new vaccine platforms like mRNA vaccines.

The Oncology segment is expected to have the highest CAGR during the forecast period

The biopharmaceutical market's highest CAGR is anticipated in the oncology segment. This is mainly because of a number of things, such as the rising incidence of cancer globally, developments in targeted and immunotherapeutic therapies, and ongoing work on precision medicine methods. Moreover, the oncology market has experienced significant growth as a result of the creation of novel biopharmaceuticals for various cancer types as well as the potential for combination therapies and biomarker-driven treatments.

Region with largest share:

The global biopharmaceutical market typically holds the largest share in the North American region, in particular the United States. A strong pharmaceutical industry, significant R&D expenditures, a developed healthcare system, a sizable patient base, and a supportive regulatory environment for the development and commercialization of biopharmaceuticals were all cited as contributing factors to this dominance. Additionally, its sizeable market share was influenced by the fact that North America is home to a large number of biopharmaceutical businesses, academic research centers, and biotechnology hubs.

Region with highest CAGR:

The biopharmaceutical market was growing at the highest CAGR in the Asia-Pacific region. A rising middle-class population, rising healthcare costs, growing pharmaceutical manufacturing capacity, and rising demand for cutting-edge treatments are just a few of the reasons for this industry's rapid growth. Due to their investments in R&D, clinical trials, and the production of biologic drugs and vaccines, nations like China and India in particular were emerging as major players in the biopharmaceutical industry. Moreover, the region's rapid growth was also aided by supportive government policies and partnerships with major pharmaceutical corporations.

Key players in the market:

Some of the key players in Biopharmaceuticals market include: Merck & Co., Inc. , Novartis AG, Abbott Laboratories., Novo Nordisk A/S, Eli Lilly and Company, AstraZeneca PLC, Bristol-Myers Squibb Company, Biogen Inc. , AbbVie Inc., Pfizer Inc., Bausch Health Companies Inc., F. Hoffmann-La Roche AG, Sanofi, Bayer AG, Allergan plc , Johnson & Johnson and Amgen Inc.

Key Developments:

In October 2023, Sanofi has reached an agreement to develop and commercialize an experimental vaccine candidate for extra intestinal pathogenic E. coli developed by Janssen Pharmaceuticals. Under the terms of the deal, Sanofi will pay the Johnson & Johnson unit $175m upfront, followed by development and commercial milestones. Both parties will co-fund current and future research and development costs. Extra intestinal pathogenic E. coli is a common gram-negative bacteria pathogen in humans and a leading cause of sepsis, particularly in older adults.

In October 2023, Bayer AG has entered into an antibody discovery, option, and license agreement with Twist Bioscience Corporation, a company offering high-quality synthetic DNA using its silicon platform. The company's Library of Libraries, a collection of synthetic antibody libraries that harnesses innovative structural and develops ability features to cover a wide range of antibody drug targets, is tailored to address specific challenges in antibody discovery. It has the potential to increase the probability of success of antibody discovery programs across indications and focus areas.

In September 2023, Abbott signs definitive agreement to acquire Bigfoot Biomedical. Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

Product Types Covered:

• Monoclonal Antibodies
• Interferon
• Insulin
• Growth and Coagulation Factor
• Vaccines
• Recombinant Growth Factors
• Purified Proteins
• Recombinant Proteins
• Synthetic Immunomodulators
• Recombinant Hormones
• Recombinant Enzymes
• Cell and Gene Therapies
• Synthetic Immunomodulators
• Other Product Types

Applications Covered:

• Oncology
• Blood disorder
• Metabolic disease
• Infectious disease
• Cardiovascular disease
• Neurological disease
• Immunology
• Autoimmune Disorders
• Hormonal Disorders
• Other Applications

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Product Analysis
• 3.7 Application Analysis
• 3.8 Emerging Markets
• 3.9 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Biopharmaceuticals Market, By Product Type

• 5.1 Introduction
• 5.2 Monoclonal Antibodies
  • 5.2.1 Anti-cancer Monoclonal Antibodies
  • 5.2.2 Anti-inflammatory Monoclonal Antibodies
• 5.3 Interferon
• 5.4 Insulin
• 5.5 Growth and Coagulation Factor
• 5.6 Vaccines
  • 5.6.1 Recombinant Vaccines
    • 5.6.1.1 Cancer Vaccine
    • 5.6.1.2 Malaria Vaccine
    • 5.6.1.3 Ebola Vaccine
    • 5.6.1.4 Hepatitis-B Vaccine
    • 5.6.1.5 Tetanus Vaccine
    • 5.6.1.6 Diphtheria Vaccine
    • 5.6.1.7 Cholera Vaccine
  • 5.6.2 Conventional Vaccines
    • 5.6.2.1 Polio Vaccine
    • 5.6.2.2 Pox Vaccine
• 5.7 Recombinant Growth Factors
  • 5.7.1 Erythropoietin
  • 5.7.2 Granulocyte Colony Stimulating Factor
• 5.8 Purified Proteins
  • 5.8.1 Leukemia Inhibitory Factor (LIF)
  • 5.8.2 P53 Protein
  • 5.8.3 P38 Protein
• 5.9 Recombinant Proteins
  • 5.9.1 Serum Albumin
  • 5.9.2 Amyloid Protein
  • 5.9.3 Defensin
  • 5.9.4 Transferrin
• 5.10 Synthetic Immunomodulators
• 5.11 Recombinant Hormones
  • 5.11.1 Recombinant Human Growth Hormones
  • 5.11.2 Recombinant Insulin
• 5.12 Recombinant Enzymes
  • 5.12.1 Enterokinase
  • 5.12.2 Cyclase
  • 5.12.3 Caspase
  • 5.12.4 Cathepsin
• 5.13 Cell and Gene Therapies
  • 5.13.1 Allogenic Products
  • 5.13.2 Autologous Products
  • 5.13.3 Acellular Products
• 5.14 Synthetic Immunomodulators
  • 5.14.1 Cytokines
  • 5.14.2 Interferons
  • 5.14.3 Interleukins
• 5.15 Other Product Types

6 Global Biopharmaceuticals Market, By Application

• 6.1 Introduction
• 6.2 Oncology
• 6.3 Blood disorder
• 6.4 Metabolic disease
• 6.5 Infectious disease
• 6.6 Cardiovascular disease
• 6.7 Neurological disease
• 6.8 Immunology
• 6.9 Autoimmune Disorders
• 6.10 Hormonal Disorders
• 6.11 Other Applications

7 Global Biopharmaceuticals Market, By Geography

• 7.1 Introduction
• 7.2 North America
  • 7.2.1 US
  • 7.2.2 Canada
  • 7.2.3 Mexico
• 7.3 Europe
  • 7.3.1 Germany
  • 7.3.2 UK
  • 7.3.3 Italy
  • 7.3.4 France
  • 7.3.5 Spain
  • 7.3.6 Rest of Europe
• 7.4 Asia Pacific
  • 7.4.1 Japan
  • 7.4.2 China
  • 7.4.3 India
  • 7.4.4 Australia
  • 7.4.5 New Zealand
  • 7.4.6 South Korea
  • 7.4.7 Rest of Asia Pacific
• 7.5 South America
  • 7.5.1 Argentina
  • 7.5.2 Brazil
  • 7.5.3 Chile
  • 7.5.4 Rest of South America
• 7.6 Middle East & Africa
  • 7.6.1 Saudi Arabia
  • 7.6.2 UAE
  • 7.6.3 Qatar
  • 7.6.4 South Africa
  • 7.6.5 Rest of Middle East & Africa

8 Key Developments

• 8.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 8.2 Acquisitions & Mergers
• 8.3 New Product Launch
• 8.4 Expansions
• 8.5 Other Key Strategies

9 Company Profiling

• 9.1 Merck & Co., Inc.
• 9.2 Novartis AG
• 9.3 Abbott Laboratories.
• 9.4 Novo Nordisk A/S
• 9.5 Eli Lilly and Company
• 9.6 AstraZeneca PLC
• 9.7 Bristol-Myers Squibb Company
• 9.8 Biogen Inc.
• 9.9 AbbVie Inc.
• 9.10 Pfizer Inc.
• 9.11 Bausch Health Companies Inc.
• 9.12 F. Hoffmann-La Roche AG
• 9.13 Sanofi
• 9.14 Bayer AG
• 9.15 Allergan plc
• 9.16 Johnson & Johnson
• 9.17 Amgen Inc.